Clinical Trials

Find trials

Perform a New Search

Search Results 1-10 of 12 for

Results filtered:
Study status: Open/Status Unknown

Edit search filters

MC230813 A Study of Golcadomide with Rituximab prior to CAR-T with Relapsed or Primary Refractory Aggressive B-cell Non-Hodgkin Lymphoma (NHL)

Albert Lea, MN, Scottsdale/Phoenix, AZ, Eau Claire, WI, Jacksonville, FL, La Crosse, WI, Mankato, MN, Rochester, MN

See Details

MC230813 A Study of Golcadomide with Rituximab prior to CAR-T with Relapsed or Primary Refractory Aggressive B-cell Non-Hodgkin Lymphoma (NHL)

Study type:
Interventional
Describes the nature of a clinical study. Types include:
- Observational study — observes people and measures outcomes without affecting results.
- Interventional study (clinical trial) — studies new tests, treatments, drugs, surgical procedures or devices.
- Medical records research — uses historical information collected from medical records of large groups of people to study how diseases progress and which treatments and surgeries work best.
Study phase:
2
During the early phases (phases 1 and 2), researchers assess safety, side effects, optimal dosages and risks/benefits. In the later phase (phase 3), researchers study whether the treatment works better than the current standard therapy. They also compare the safety of the new treatment with that of current treatments. Phase 3 trials include large numbers of people to make sure that the result is valid. There are also less common very early (phase 0) and later (phase 4) phases. Phase 0 trials are small trials that help researchers decide if a new agent should be tested in a phase 1 trial. Phase 4 trials look at long-term safety and effectiveness, after a new treatment has been approved and is on the market.

About this study

The purpose of this study is to evaluate efficacy as measured by the disease control rate (CMR, PMR, and NMR) by Lugano 2014 PET-CT based assessment after 2 cycles of therapy.

Participating Mayo Clinic locations

Study statuses change often. Please contact us for help.

Mayo Clinic Location	Status	Contact
Rochester, Minn.	Open for enrollment	View complete study & contact information
Mankato, Minn.	Open for enrollment
Jacksonville, Fla.	Open for enrollment
La Crosse, Wis.	Open for enrollment
Eau Claire, Wis.	Open for enrollment
Scottsdale/Phoenix, Ariz.	Open for enrollment
Albert Lea, Minn.	Open for enrollment

Print study details

Site IRB:
- Rochester, Minnesota: 24-005122
- Mankato, Minnesota: 24-005122
- Jacksonville, Florida: 24-005122
- La Crosse, Wisconsin: 24-005122
- Eau Claire, Wisconsin: 24-005122
- Scottsdale/Phoenix, Arizona: 24-005122
- Albert Lea, Minnesota: 24-005122
NCT ID:
NCT06834373
Sponsor Protocol Number:
MC230813

Mayo Clinic Location	Status	Contact
Rochester, Minn.	Contact us for the latest status	View complete study & contact information

Mayo Clinic Location	Status	Contact
Rochester, Minn.	Contact us for the latest status	View complete study & contact information

Compare the Efficacy and Safety of Golcadomide Plus R-CHOP vs Placebo Plus RCHOP in Participants with Previously Untreated High-risk Large B-cell Lymphoma

Scottsdale/Phoenix, AZ, Jacksonville, FL, Rochester, MN

See Details

Compare the Efficacy and Safety of Golcadomide Plus R-CHOP vs Placebo Plus RCHOP in Participants with Previously Untreated High-risk Large B-cell Lymphoma

Study type:
Interventional
Describes the nature of a clinical study. Types include:
- Observational study — observes people and measures outcomes without affecting results.
- Interventional study (clinical trial) — studies new tests, treatments, drugs, surgical procedures or devices.
- Medical records research — uses historical information collected from medical records of large groups of people to study how diseases progress and which treatments and surgeries work best.
Study phase:
3
During the early phases (phases 1 and 2), researchers assess safety, side effects, optimal dosages and risks/benefits. In the later phase (phase 3), researchers study whether the treatment works better than the current standard therapy. They also compare the safety of the new treatment with that of current treatments. Phase 3 trials include large numbers of people to make sure that the result is valid. There are also less common very early (phase 0) and later (phase 4) phases. Phase 0 trials are small trials that help researchers decide if a new agent should be tested in a phase 1 trial. Phase 4 trials look at long-term safety and effectiveness, after a new treatment has been approved and is on the market.

About this study

The purpose of this study is to evaluate the efficacy of golcadomide plus R-CHOP vs placebo-R-CHOP in participants with untreated high-risk large B-cell lymphoma with respect to PFS as assessed by the investigator.

Participating Mayo Clinic locations

Study statuses change often. Please contact us for help.

Mayo Clinic Location	Status	Contact
Jacksonville, Fla.	Open for enrollment	View complete study & contact information
Rochester, Minn.	Open for enrollment
Scottsdale/Phoenix, Ariz.	Open for enrollment

Print study details

Site IRB:
- Jacksonville, Florida: 24-004587
- Rochester, Minnesota: 24-004587
- Scottsdale/Phoenix, Arizona: 24-004587
NCT ID:
NCT06356129
Sponsor Protocol Number:
CA0731020

Ascorbic Acid and Combination Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma or CCUS

Rochester, MN, La Crosse, WI, Eau Claire, WI, Mankato, MN

See Details

Ascorbic Acid and Combination Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma or CCUS

Study type:
Interventional
Describes the nature of a clinical study. Types include:
- Observational study — observes people and measures outcomes without affecting results.
- Interventional study (clinical trial) — studies new tests, treatments, drugs, surgical procedures or devices.
- Medical records research — uses historical information collected from medical records of large groups of people to study how diseases progress and which treatments and surgeries work best.
Study phase:
2
During the early phases (phases 1 and 2), researchers assess safety, side effects, optimal dosages and risks/benefits. In the later phase (phase 3), researchers study whether the treatment works better than the current standard therapy. They also compare the safety of the new treatment with that of current treatments. Phase 3 trials include large numbers of people to make sure that the result is valid. There are also less common very early (phase 0) and later (phase 4) phases. Phase 0 trials are small trials that help researchers decide if a new agent should be tested in a phase 1 trial. Phase 4 trials look at long-term safety and effectiveness, after a new treatment has been approved and is on the market.

About this study

The purpose of this study is to examine how well ascorbic acid and combination chemotherapy work in treating patients with lymphoma that has come back or does not respond to therapy. Ascorbic acid may make cancer cells more sensitive to chemotherapy. Drugs used in chemotherapy, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving ascorbic acid and combination chemotherapy may work better at treating lymphoma.

In the Clonal Cytopenia of Undetermined Significance (CCUS) Cohort D, we want to find out if ascorbic acid will improve blood counts so fewer transfusions are required and there is a less likely chance the patient will develop myelodysplastic syndrome (MDS) or other related myeloid malignancies.

Participating Mayo Clinic locations

Study statuses change often. Please contact us for help.

Mayo Clinic Location	Status	Contact
Rochester, Minn.	Open for enrollment	View complete study & contact information
Mankato, Minn.	Contact us for the latest status
La Crosse, Wis.	Closed for enrollment
Eau Claire, Wis.	Contact us for the latest status

Print study details

Site IRB:
- Rochester, Minnesota: 17-008096
- Mankato, Minnesota: 17-008096
- La Crosse, Wisconsin: 17-008096
- Eau Claire, Wisconsin: 17-008096
NCT ID:
NCT03418038
Sponsor Protocol Number:
LS1781

Epcoritamab Compared to Observation for Treating B-cell Lymphoma Patients Not in Complete Remission After CD19-directed CAR-T Therapy

Jacksonville, FL, Rochester, MN
- See Details
Epcoritamab Compared to Observation for Treating B-cell Lymphoma Patients Not in Complete Remission After CD19-directed CAR-T Therapy
- Study type:
  Interventional
  Describes the nature of a clinical study. Types include:
  
  Observational study — observes people and measures outcomes without affecting results.
  
  Interventional study (clinical trial) — studies new tests, treatments, drugs, surgical procedures or devices.
  
  Medical records research — uses historical information collected from medical records of large groups of people to study how diseases progress and which treatments and surgeries work best.
- Study phase:
  2
  During the early phases (phases 1 and 2), researchers assess safety, side effects, optimal dosages and risks/benefits. In the later phase (phase 3), researchers study whether the treatment works better than the current standard therapy. They also compare the safety of the new treatment with that of current treatments. Phase 3 trials include large numbers of people to make sure that the result is valid. There are also less common very early (phase 0) and later (phase 4) phases. Phase 0 trials are small trials that help researchers decide if a new agent should be tested in a phase 1 trial. Phase 4 trials look at long-term safety and effectiveness, after a new treatment has been approved and is on the market.
About this study

The purpose of this study is to compare epcoritamab to standard practice (observation) for the treatment of patients with B-cell lymphomas who are not in complete remission after treatment with CD19-directed chimeric antigen receptor T-cell (CAR-T) therapy.

Participating Mayo Clinic locations

Study statuses change often. Please contact us for help.

Mayo Clinic Location Status Contact

Rochester, Minn.

Open for enrollment
View complete study & contact information

Jacksonville, Fla.

Open for enrollment

Print study details
Site IRB:
Rochester, Minnesota: 24-000568
Jacksonville, Florida: 24-000568

NCT ID:
NCT06238648

Sponsor Protocol Number:
ACCRU-LY-2201

Axicabtagene Ciloleucel versus Standard of Care Therapy as First-Line Therapy in High-Risk Large B-Cell Lymphoma

Scottsdale/Phoenix, AZ, Rochester, MN, Albert Lea, MN, Eau Claire, WI, La Crosse, WI, Mankato, MN

See Details

Axicabtagene Ciloleucel versus Standard of Care Therapy as First-Line Therapy in High-Risk Large B-Cell Lymphoma

Study type:
Interventional
Describes the nature of a clinical study. Types include:
- Observational study — observes people and measures outcomes without affecting results.
- Interventional study (clinical trial) — studies new tests, treatments, drugs, surgical procedures or devices.
- Medical records research — uses historical information collected from medical records of large groups of people to study how diseases progress and which treatments and surgeries work best.
Study phase:
3
During the early phases (phases 1 and 2), researchers assess safety, side effects, optimal dosages and risks/benefits. In the later phase (phase 3), researchers study whether the treatment works better than the current standard therapy. They also compare the safety of the new treatment with that of current treatments. Phase 3 trials include large numbers of people to make sure that the result is valid. There are also less common very early (phase 0) and later (phase 4) phases. Phase 0 trials are small trials that help researchers decide if a new agent should be tested in a phase 1 trial. Phase 4 trials look at long-term safety and effectiveness, after a new treatment has been approved and is on the market.

About this study

The purpose of this study is to compare the effectiveness of axicabtagene ciloleucel versus standard of care therapy (SOCT), as measured by eventfree survival (EFS). Additionally, to compare the effectiveness of axicabtagene ciloleucel versus SOCT, as measured by progression-free survival (PFS) and overall survival (OS).

Participating Mayo Clinic locations

Study statuses change often. Please contact us for help.

Mayo Clinic Location	Status	Contact
Rochester, Minn.	Open for enrollment	View complete study & contact information
Eau Claire, Wis.	Open for enrollment
La Crosse, Wis.	Open for enrollment
Mankato, Minn.	Open for enrollment
Scottsdale/Phoenix, Ariz.	Open for enrollment
Albert Lea, Minn.	Open for enrollment

Print study details

Site IRB:
- Rochester, Minnesota: 23-006955
- Eau Claire, Wisconsin: 23-006955
- La Crosse, Wisconsin: 23-006955
- Mankato, Minnesota: 23-006955
- Scottsdale/Phoenix, Arizona: 23-006955
- Albert Lea, Minnesota: 23-006955
NCT ID:
NCT05605899
Sponsor Protocol Number:
KT-US-484-0136

Pagination Clinical studies

Clinical Trials

Filter Results

Locations

Study status

Gender

Age

Study phase

Search Results 1-10 of 12 for

MC230813 A Study of Golcadomide with Rituximab prior to CAR-T with Relapsed or Primary Refractory Aggressive B-cell Non-Hodgkin Lymphoma (NHL)

Cellular Immunotherapy for Viral Induced Cancer - EBV Positive Lymphomas

DALY 2.0 USA/ MB-CART2019.1 for DLBCL

A Study to Provide Access to CTL019 Out of Specification Managed Access Program (MAP) for ALL or DLBCL Patients

Safety/Efficacy of MEDI-551 in Combination With Immunomodulating Therapies in Subjects With Aggressive B-cell Lymphomas

Phase 2 Study with TTI-622 and TTI-621 in Relapsed Diffuse Large B-Cell Lymphoma (DLBCL)

Compare the Efficacy and Safety of Golcadomide Plus R-CHOP vs Placebo Plus RCHOP in Participants with Previously Untreated High-risk Large B-cell Lymphoma

Ascorbic Acid and Combination Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma or CCUS

Epcoritamab Compared to Observation for Treating B-cell Lymphoma Patients Not in Complete Remission After CD19-directed CAR-T Therapy

Axicabtagene Ciloleucel versus Standard of Care Therapy as First-Line Therapy in High-Risk Large B-Cell Lymphoma

Mayo Clinic Footer

Legal Conditions and Terms

Advertising

Reprint Permissions